Literature DB >> 19629730

Modeling the transition of lung cancer from early to advanced stage.

Maksim A Pashkevich1, Bronislava M Sigal, Sylvia K Plevritis.   

Abstract

We present a stochastic parametric model of the natural history of lung cancer that predicts the primary tumor volume at the moment the disease transits from early to advanced stage. Our model also produces estimates for the probability of symptomatic detection as a function of tumor volume and clinical stage. We estimate model parameters by likelihood maximization using data from the Mayo Lung Project (MLP), which was a clinical trial that evaluated screening for lung cancer in the 1970s. Mayo Lung Project cancer cases reported in Stage III or greater, according to the 1979 AJCC staging for lung cancer, were considered advanced stage. Our estimator distinguishes between the cases detected because of clinical symptoms and cases detected by screening. For nonsmall cell lung cancer cases detected in MLP, we estimate that the median primary tumor diameter at the onset of advanced stage disease was 4.1 cm. In addition, we estimate that the rate of patients symptomatically detected with their disease increases as their primary tumor increases in size, and for patients with a primary tumor of a given size, the rate of symptomatic detection is 12.8 times greater among patients with advanced stage disease compared to patients with early stage disease.

Entities:  

Mesh:

Year:  2009        PMID: 19629730     DOI: 10.1007/s10552-009-9401-4

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  4 in total

1.  Obligate progression precedes lung adenocarcinoma dissemination.

Authors:  Deborah R Caswell; Chen-Hua Chuang; Dian Yang; Shin-Heng Chiou; Shashank Cheemalavagu; Caroline Kim-Kiselak; Andrew Connolly; Monte M Winslow
Journal:  Cancer Discov       Date:  2014-04-16       Impact factor: 39.397

2.  Comparing the benefits of screening for breast cancer and lung cancer using a novel natural history model.

Authors:  Ray S Lin; Sylvia K Plevritis
Journal:  Cancer Causes Control       Date:  2011-11-25       Impact factor: 2.506

3.  Longitudinal multistage model for lung cancer incidence, mortality, and CT detected indolent and aggressive cancers.

Authors:  William D Hazelton; Gary Goodman; William N Rom; Melvyn Tockman; Mark Thornquist; Suresh Moolgavkar; Joel L Weissfeld; Ziding Feng
Journal:  Math Biosci       Date:  2012-06-15       Impact factor: 2.144

4.  Targeted codelivery of doxorubicin and IL-36γ expression plasmid for an optimal chemo-gene combination therapy against cancer lung metastasis.

Authors:  Yichao Chen; Jingjing Sun; Yixian Huang; Yanhua Liu; Lei Liang; Da Yang; Binfeng Lu; Song Li
Journal:  Nanomedicine       Date:  2018-10-08       Impact factor: 5.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.